Progress and Prospects in Parkinson's Research

This is Section 1 of The science behind Parkinson's disease - a Wikiversity learning project.

This Section is for those who are interested in following research into Parkinson's and thinking about what questions remain unanswered, what issues need to be resolved and what implications arise from research results.

Below are topics which contributors wish to bring to the attention of others.

But there is also a 'Magazine Section' dealing with articles to enable readers to get an overview of the current 'Hot Topics' and read discussions of key issues. These articles will link to the main body of the learning project.

Purpose of Section 1: To enable contributors:

to highlight interesting topics in current Parkinson's research
to explain their significance and background
to describe the questions answered and identify the questions still unanswered
to say how the work fits into the bigger picture and what other researchers are doing
to examine hypotheses and to raise implications
to identify possible new lines of enquiry and new implications for research strategy

Topics

Topics below in red are those thought to be important but have not been worked on yet. You are invited to start them.

You are welcome to add topics you believe are important.

**Topics for Progress and Prospects in Parkinson's Research**
Main field	Topic	Subpages
Researching Parkinson's	Modelling PD	Animal Models, Rotenone Model, Induced Pluripotent Stem Cells, A pathogenesis map
	Hot Topics	Vitamin D, Role of alpha-synuclein in pathogenesis, Neuroprotective agents, Biomarkers and Biomeasures, Induced Pluripotent Stem Cells, Genome-Wide Association Studies, Getting Drugs from Lab to Clinic
Causes	Inheritance	SNCA, LRRK2, MAPT, GBA, HLA
	Trauma	Cysts, Vascular PD,
	Infection	Helicobacter pylori, Influenza, Lipopolysaccharide, Melanoma, Whooping cough,
	Deficiencies	Blood, Glutathione, Melatonin, Norepinephrine, Vitamin D, Zinc
	Toxins	Cadmium, Copper, Dieldrin, Manganese, Maneb, Mercury, MPTP, n-Hexane, Paraquat, Rotenone, Toluene, Trichloroethylene, Ziram,
Pathogenesis	Current Parkinson's Paradigm	Working Hypothesis, Emerging Hypotheses, Oxidative Stress, Inflammation, Role of alpha-synuclein, A pathogenesis map
Symptoms
Therapy	Transplantation
	Symptomatic Relief	Bradykinesia -, Dyskinesia -, Festination -, Freezing -, Non-motor symptoms - Sleep Disturbance -, Tremor,
	Exercise	Effect on symptoms, Neuroproective effects
	Neuroprotection	Neuroprotective agents, Caffeine,-- Celastrol,-- Co-enzyme Q10,-- Creatine,-- DHA,-- Exendin-4 (EX-4),-- GDNF,-- Glutathione (GSH),-- GM1,-- Herbal Remedies,-- Isradipine,-- Melatonin,-- Mirapex,-- Minocycline,-- Nicotine,-- NSAIDs,-- Phenylbutyrate,-- Phytic Acid,-- Probucol,-- Quinoxaline,-- Rasagiline,-- Riboflavin,-- Statins,-- Tolcapone,-- Urate & Uric Acid-- Vitamin D,-- Vitamin E,--
	Gene Therapy	RNA interference
	From Lab to Clinic	Clinical trials and the route to market
Monitoring Disease	Biomarkers, Measurement of Disease Progression
Atypical parkinsonism	MSA, PSP, DLB, ET, CBD,

PD Map

Moved to: Parkinson's_Pathogenesis/PD_Map with Magazine Section article at PD_Magazine_Section/PD_pathogenesis_map

References

This article is issued from Wikiversity. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.